Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 218

Results For "LTI"

2566 News Found

Medtronic gets USFDA approval of spinal cord stimulation therapy
Medical Device | January 25, 2022

Medtronic gets USFDA approval of spinal cord stimulation therapy

Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone


RaphaCure partners with Madhavbaug for cardiac healthcare services
Clinical Trials | January 24, 2022

RaphaCure partners with Madhavbaug for cardiac healthcare services

Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals


USFDA approves IND application for Allied’s cancer treatment
Biotech | January 24, 2022

USFDA approves IND application for Allied’s cancer treatment

APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types


Omicron is now in community transmission in India: INSACOG
News | January 23, 2022

Omicron is now in community transmission in India: INSACOG

The country is sixth among the most affected countries by active cases


Bristol Myers Squibb receives approval for Abecma in Japan
Drug Approval | January 21, 2022

Bristol Myers Squibb receives approval for Abecma in Japan

It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan


Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir
Drug Approval | January 21, 2022

Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir

The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list


Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
News | January 21, 2022

Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22

Biocon has reported consolidated financial results for the period ended December 31, 2021


US FDA approves Idorsia’s insomnia drug
Drug Approval | January 21, 2022

US FDA approves Idorsia’s insomnia drug

Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain


Natco Pharma signs agreement with Medicines Patent Pool
News | January 20, 2022

Natco Pharma signs agreement with Medicines Patent Pool

This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name


Healthcare for seniors an opportunity for service providers
Public Health | January 19, 2022

Healthcare for seniors an opportunity for service providers

Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas